SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...
If there’s one constant with software developers, it is that sometimes they get bored. At these times, they tend to think ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback